Advertisement

Topics

ARCA biopharma, Inc. Company Profile

04:09 EDT 25th June 2018 | BioPortfolio

ARCA biopharma is dedicated to developing genetically targeted therapies for heart failure and other cardiovascular disease. The Company's lead product candidate, bucindolol hydrochloride, is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for heart failure. ARCA has identified common genetic variations that it believes predict individual patient response to bucindolol, giving it the potential to be the first genetically-targeted heart failure treatment. ARCA is collaborating with Laboratory Corporation of America to develop the companion genetic test for bucindolol. For more information please visit www.arcabiopharma.com.


News Articles [1495 Associated News Articles listed on BioPortfolio]

Arca Biopharma, Medtronic extend trial collaboration deal

A clinical trial collaboration agreement in the US, Canada and Europe between Medtronic and Arca Biopharma was extended until -More- 

Shares Plunge as ARCA biopharma’s Gencaro Had Mixed Phase II Clinical Trial Results

ARCA biopharma announced positive headline results from its Phase IIb clinical trial of Gencaro, but investors aren't buying the positive spin.

ARCA biopharma Announces Completion of GENETIC-AF Phase 2B Clinical Trial

-------------------------------------------------------------------------------------------------- GENETIC-AF Evaluating Gencaro as Potentially First Genetically-Targeted Treatment for Atrial Fib...

ARCA biopharma Reports Topline Phase 2B Results for GENETIC-AF Clinical Trial

-------------------------------------------------------------------------------------------------- Gencaro Demonstrates Comparable Efficacy to Active Control and Trend for Potential Gencaro S...

ARCA biopharma and Medtronic Extend Gencaro Clinical Trial Collaboration Agreement

WESTMINSTER, Colo., April 23, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted th...

ARCA Biopharma announces first quarter 2018 financial results AND Provides Corporate Update

WESTMINSTER, Colo., May 08, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therap...

ARCA biopharma Announces Fiscal Year 2017 Financial Results and Provides Corporate Update

WESTMINSTER, Colo., March 22, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted th...

Your Daily Pharma Scoop: Progenics Update, La Jolla Data, ARCA Biopharma Setback

Drugs and Medications [6 Associated Drugs and Medications listed on BioPortfolio]

Cardene® sr [PDL BioPharma, Inc.]

CARDENE® SR

Recombinate [Baxter Healthcare Corporation]

RECOMBINATE [Antihemophilic Factor (Recombinant)]

Recombinate [Baxter Healthcare Corporation]

RECOMBINATE [Antihemophilic Factor (Recombinant)]

Recombinate [Baxter Healthcare Corporation]

RECOMBINATE [Antihemophilic Factor (Recombinant)]

Recombinate [Baxter Healthcare Corporation]

RECOMBINATE [Antihemophilic Factor (Recombinant)]

PubMed Articles [6 Associated PubMed Articles listed on BioPortfolio]

Rethinking the Clinically Based Thresholds of TransCelerate BioPharma for Risk-Based Monitoring.

The quality of data from clinical trials has received a great deal of attention in recent years. Of central importance is the need to protect the well-being of study participants and maintain the inte...

Holocene ecosystem shifts and human-induced loss of Arca and Ostrea shell beds in the north-eastern Adriatic Sea.

The molluscan assemblages in a sediment core from the north-eastern Adriatic show significant compositional changes over the past 10,000yrs related to (1) natural deepening driven by the post-glacial ...

All three quinone species play distinct roles in ensuring optimal growth under aerobic and fermentative conditions in E. coli K12.

The electron transport chain of E. coli contains three different quinone species, ubiquinone (UQ), menaquinone (MK) and demethylmenaquinone (DMK). The content and ratio of the different quinone specie...

The positive impacts of Real-World Data on the challenges facing the evolution of biopharma.

Demand for healthcare services is unprecedented. Society is struggling to afford the cost. Pricing of biopharmaceutical products is under scrutiny, especially by payers and Health Technology Assessmen...

A network of regulators promotes dehydration tolerance in Escherichia coli.

The ability to survive conditions of low water activity is critical for the survival of many bacteria in the environment and facilitates disease transmission through food and contaminated surfaces. Ho...

Clinical Trials [3 Associated Clinical Trials listed on BioPortfolio]

Single Ascending Dose Phase 1 Trial in Patients With Type 2 Diabetes

ARRY-403 is an investigational new drug being developed by Array BioPharma Inc. for treating Type 2 diabetes. The purpose of this study is to test the safety (potential side effects) and ...

A Phase 1b Study Evaluating RESTEN-MP in Subjects With Focal de Novo Stenosis

The process of re-narrowing of a coronary artery following a revascularization procedure such as angioplasty, begins at the time of the procedure. Restenosis has long been considered a ma...

Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Stent in Coronary Arteries

The process of re-narrowing of a coronary artery following a revascularization procedure such as angioplasty, begins at the time of the procedure. Restenosis has long been considered a ma...

Companies [135 Associated Companies listed on BioPortfolio]

ARCA biopharma, Inc.

ARCA biopharma is dedicated to developing genetically targeted therapies for heart failure and other cardiovascular disease. The Company's lead product candidate, bucindolol hydro...

SAFE-BioPharma Association

SAFE-BioPharma Association (www.safe-biopharma.org) is the non-profit association that created and manages the SAFE-BioPharma® digital identity and signature standard for the ...

Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged primarily in the development of targeted cancer therapies. For more information on the Company, visit http://www.genesis-b...

SAFE-BioPharma Association, LLC

As part of the National Health Information Sharing and Analysis Center (NH-ISAC), SAFE-BioPharma Association, LLC [www.safe-biopharma.org] provides global, high-assurance identity...

TenX Biopharma, Inc.

TenX Biopharma, Inc., is a biopharmaceutical company focused on late stage development and commercialization of novel monoclonal antibody-based cancer therapies. TenX Biopharma acquired global rights ...

More Information about "ARCA biopharma, Inc." on BioPortfolio

We have published hundreds of ARCA biopharma, Inc. news stories on BioPortfolio along with dozens of ARCA biopharma, Inc. Clinical Trials and PubMed Articles about ARCA biopharma, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ARCA biopharma, Inc. Companies in our database. You can also find out about relevant ARCA biopharma, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...


Corporate Database Quicklinks



Searches Linking to this Company Record